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Abstract
Non-alcoholic fatty liver disease (NAFLD) is a growing health problem with a global prevalence of over 25% and 
prevalence rates of over 60% in high-risk populations. It is considered the hepatic component of the metabolic 
syndrome and is associated with an increased risk of the development of various liver-associated and cardiometabolic 
complications. Given the complexity of NAFLD and associated comorbidities and complications, treatment requires 
interventions from a variety of different healthcare specialties. However, many clinicians are currently insufficiently 
aware of the potential harm and severity of NAFLD and associated comorbidities, complications and the steps that 
should be taken when NAFLD is suspected. Recognizing which patients suffer from non-progressive simple steatosis, 
metabolically active NASH with high risk of developing cardiovascular disease and which patients have a high risk of 
developing cirrhosis and hepatocellular carcinoma is important. Unfortunately, this can be difficult and guidelines 
towards the optimal diagnostic and therapeutic approach are ambivalent. Here we review the pathogenesis, 
diagnostics and treatment of NAFLD and discuss how multidisciplinary care path development could move forward.
Introduction
Worldwide, the amount of people leading a so-called 
‘Western lifestyle’, an unhealthy high-caloric diet and 
only little exercise, has increased tremendously. Associated 
with this ‘Western lifestyle’ are obesity and the metabolic 
syndrome, a term used for the coexistence of an increased 
abdominal fat mass, hyperglycaemia, hypertension and 
dyslipidaemia. Non-alcoholic fatty liver disease (NAFLD) 
is considered to be the hepatic component of metabolic 
syndrome (1, 2). NAFLD is defined by accumulation 
of intracellular fat in >5% of hepatocytes on imaging 
or histology, in the absence of other causes of hepatic 
steatosis such as excessive alcohol intake, certain 
metabolic conditions or drug use (3).
In concert with the increase in prevalence rates 
of obesity and metabolic syndrome, the prevalence of 
NAFLD has increased dramatically to over 25% of the 
population worldwide (4). In high-risk populations, like 
patients with type 2 diabetes mellitus (T2DM), prevalence 
rates are even estimated to be over 60% (5). The high 
prevalence of NAFLD and the associated complications 
and comorbidities, including T2DM and cardiovascular 
disease, result in a large burden on healthcare, associated 
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costs, a reduction of quality of life and increased mortality 
rates (3, 6, 7, 8).
NAFLD encompasses a spectrum of disease stages. It 
varies from simple hepatic steatosis, also known as non-
alcoholic fatty liver (NAFL), to steatohepatitis (NASH) 
and development of fibrosis and can eventually progress 
to cirrhosis and hepatocellular carcinoma (HCC) (Fig. 1) 
(6). Although NAFLD is very common, only a part of the 
patients with hepatic steatosis will develop advanced 
stage liver disease. However, when NAFLD progresses to 
a more severe liver disease, potential lethal complications 
like ascites, oesophageal varices, hepatic encephalopathy, 
HCC and liver failure may arise. It is important to 
differentiate between patients with non-progressive 
simple steatosis and patients with metabolically active 
NASH with high risk of developing cardiovascular disease 
or those with an increased risk of developing cirrhosis and 
HCC. Unfortunately, recognizing these at-risk patients 
can be difficult and guidelines on the optimal diagnostic 
and therapeutic approach are ambivalent. As a result, 
many clinicians are currently insufficiently aware of the 
steps that should be taken when NAFLD is suspected or 
newly diagnosed. A fundamental aspect of this problem 
is the paucity of a common healthcare path for NAFLD 
covering the complexity and multidisciplinary character 
of this potential harmful disease (9).
Here we review the pathogenesis, diagnostics 
and treatment of NAFLD and aim to provide a clear 
overview of the diagnostic options, clinical care strategies 
and recommendations for the development of a 
multidisciplinary care path.
Pathogenesis
The pathogenesis of NAFLD is complex. We give a 
graphical overview in Fig. 2. For extensive detail, we refer 
to excellent recent reviews (2, 4, 10).
In brief, an interaction of environmental factors, 
diet and genetics results in alterations of multiple factors 
and pathways of glucose and lipid metabolism that 
constitute vicious circles, leading to progressive stages of 
NAFLD. Centrally stands insulin resistance, which causes 
an increased flux of circulating free fatty acids (FFAs) to 
the liver, through reduced insulin-mediated suppression 
of lipolysis in adipose tissue (11, 12, 13). These FFAs are 
stored as triglycerides in lipid droplets, reducing hepatic 
insulin sensitivity and consequently increasing hepatic 
gluconeogenesis, which results in hyperglycaemia 
and intrahepatic conversion of glucose to FFAs (14). 
Meanwhile, high plasma insulin levels increase de novo 
lipogenesis, producing even more triglycerides and further 
Figure 1
The disease spectrum of non-alcoholic 
fatty liver disease (NAFLD).
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enhancing hepatic gluconeogenesis. As shown in Fig. 2, 
this cycle of processes causes an abundance of FFAs and 
triglycerides. When hepatic compensatory mechanisms 
fall short, lipotoxicity occurs, causing mitochondrial 
dysfunction, resulting in formation of reactive oxygen 
species (oxidative stress), inflammation and cell damage 
(15, 16, 17).
The overload of circulating FFAs triggers pro-
inflammatory pathways (c-jun terminal kinase (JNK) via 
apoptosis signal-regulating kinase 1 (ASK-1), and nuclear 
factor kappa-light-chain-enhancer of activated B-cells (NF-κB)), 
leading to inflammation, fibrosis and hepatocyte cell death 
or apoptosis (18, 19). Another pro-inflammatory pathway 
in NAFLD is formed by the production of cytokines by 
the visceral fat tissue, the so-called adipocytokines, such 
as IL-6 and TNF-α. These adipocytokines are directly 
transported to the liver through the portal system and 
cause a pro-inflammatory hepatic environment (18, 20, 
21), resulting in activation of Kupffer and stellate cells and 
leading to fibrosis (22, 23, 24). Various other hepatokines 
have been shown to play a role in the development of 
NAFLD-NASH, as reviewed elsewhere (25).
Furthermore, dysregulation of the urea cycle may 
be involved in the pathogenesis of NAFLD, causing a 
build-up of toxic ammonia, potentially as a result of 
mitochondrial dysfunction (26). Many other factors have 
been implicated in the pathogenesis of NAFLD, including 
bile acid signalling and the gut microbiome (27, 28).
With respect to genetics, variations in genes involved 
in lipid metabolism and VLDL export (i.e. PNPLA3, 
TM6SF2, MBOAT7 and HSD17B13) have been found 
to exert an effect on the complex pathophysiologic 
mechanisms involved in the development of NAFLD and 
NASH (29, 30, 31, 32).
Diagnostics
There is a clear need for good diagnostic tests for 
NAFLD-NASH. The limited sensitivity of available tests 
(liver enzymes and ultrasound), as well as the limited 
implementation of more sensitive diagnostic modalities 
such as the Fibrosis-4 (FIB-4) score and vibration controlled 
transient elastography (VCTE), have turned this into 
a very active development area of the NAFLD research 
field, with a variety of diagnostic tests available and in 
development. The performance of diagnostic tests is 
linked to the prevalence within the tested population and 
Figure 2
The pathogenesis of non-alcoholic fatty 
liver disease (NAFLD).
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therefore, different tests should be used in primary care 
versus secondary or tertiary care and test results should 
be interpreted accordingly. Table 1 shows an overview of 
available tests, their contexts of use, costs, accuracy and 
(dis)advantages.
Most patients with NAFLD express (slightly) elevated 
serum liver enzymes, in particular ALT and γGT. However, 
liver enzymes within the reference range do not exclude 
NAFLD, and although elevated liver enzymes may serve as 
a diagnostic clue for the presence of liver disease, they fail 
to predict the presence and severity of hepatic steatosis, 
inflammation (NASH) and fibrosis (33). Therefore, various 
scores have been developed to estimate these aspects of 
NAFLD in a non-invasive way, such as the Fatty Liver Index 
(FLI) for steatosis (34) and the FIB-4 score for fibrosis (35).
FLI is an algorithm that combines BMI, waist 
circumference, γGT and triglyceride levels to predict 
the presence of hepatic steatosis with good accuracy as 
compared to MR or spectroscopy (36). However, it does 
not identify patients with more advanced disease (NASH 
or advanced fibrosis). Therefore, FLI is a useful tool in 
epidemiological studies, but it is not considered useful in 
a clinical setting (37).
The FIB-4 score is a calculative score based on age, 
AST and ALT levels and platelet count. It can be used to 
distinguish patients likely to have advanced fibrosis from 
those who do not, while keeping in mind the predictive 
value of the test for the specific patient at the chosen 
threshold (38). This test recently performed well in a 
care path in the United Kingdom and guides referral of 
patients to secondary health care for further analysis and 
surveillance for cirrhosis associated diseases including 
oesophageal varices and HCC.
The NAFLD fibrosis score (NFS) is a calculative score 
that takes into account an impaired fasting glucose or 
diabetes, age, AST and ALT, platelet count, BMI and 
albumin. This score performs similarly to FIB-4 for ruling 
out advanced fibrosis (39).
Another test aimed at identifying patients with 
liver fibrosis is the Enhanced Liver Fibrosis (ELF) test. 
This test combines three serum markers of hepatic 
matrix metabolism: hyaluronic acid, pro-collagen III 
amino terminal peptide (PIIINP) and tissue inhibitor of 
metalloproteinase-1 (TIMP-1) and therefore more closely 
represents the biological process of fibrosis formation 
(40). It can also be used to monitor disease progression 
and response to treatment.
Thus far, no non-invasive biomarker or score exists that 
has both high sensitivity and specificity and is applicable 
to a wide population of patients and the search for such 
a marker is on-going. A plethora of biomarkers and scores 
are currently being tested and validated in large-scale 
European (LITMUS) (41) and American (NIMBLE) NAFLD 
biobank studies (35, 39, 42).
Ultrasonography, in which the reflection pattern of 
the liver is compared with the kidneys and/or spleen, is 
a tool often used to determine the presence and extent 
of hepatic steatosis (43). This diagnostic test is widely 
available (especially in primary care) and of low cost, 
although its sensitivity is limited in patients with moderate 
steatosis (<20%) and in those with a BMI > 40 kg/m2 (44). 
Furthermore, ultrasonography cannot determine the 
presence and extent of inflammation (NASH) and fibrosis. 
Therefore, it can be used to rule out other causes of 
abnormal liver function tests, but it is not sufficient to be 
used for risk-stratification or to guide referral of patients 
suspected of NASH or fibrosis.
‘Vibration controlled’ transient elastography, VCTE™ 
or FibroScan® (brand name) is a non-invasive tool 
that can be used to measure the elasticity of the liver, 
thereby determining the presence and extent of fibrosis 
(45). This technique uses the simultaneous emission 
of both sonographic and electrical waves. Using the 
velocity of wave transmission through the tissue, it 
estimates liver elasticity: the faster the wave, the stiffer 
the tissue, as in fibrosis. By also using the extinguishment 
of the ultrasonography signal (the so called continued 
attenuation parameter, or CAP™), it estimates the amount 
of hepatic steatosis. VCTE/CAP was recently shown to 
be very accurate for both steatosis and cirrhosis over the 
incremental stages of NAFLD (45). Combined with its 
ease of use, we therefore expect the application of VCTE/
CAP to increase in both primary and secondary care over 
the next few years, although the significant cost of the 
equipment may hamper this development.
The most accurate non-invasive method to diagnose 
and quantify hepatic steatosis is magnetic resonance 
imaging (MRI), especially using the so-called proton 
density fat fraction (PDFF) technique (46). Recently, a 
new multiparametric MR index has been proposed for 
diagnosing NASH, in which MR spectrography (MRS), 
MR elastography (MRE) and T1 mapping were combined 
in order to cover the various components of NASH. In a 
small group of 20 NASH and 27 non-NASH patients, this 
multiparametric MR index was shown to have an AUC of 
0.883, which needs to be validated in larger NAFLD cohorts 
(47). However, because magnetic resonance imaging is 
time-consuming, expensive, of limited availability and its 
validity to measure fibrosis has not yet been confirmed, it 
is currently less suited for clinical use.
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To date, liver biopsy remains the gold standard for 
diagnosing NASH, in which the characteristic swelling of 
hepatocytes (ballooning) and lobular inflammation can 
be established (Fig. 1). An important additional benefit 
of liver biopsy is the possibility to assess the presence 
and extent of liver fibrosis. However, liver biopsy is an 
invasive procedure that can be painful, has a risk of post-
biopsy bleeding (up to 2%) and might convey a sampling 
error, due to only about 1/50.000th of the liver tissue being 
analysed, while NAFLD is often not equally distributed 
throughout the liver (48).
Clear numbers on specificity, sensitivity and potential 
risks of the diagnostic tools listed above are lacking 
because of large differences in methodology of clinical 
studies, which hampers their comparability. Therefore, 
diagnostic decisions should be made individually based 
on the specific case, the available diagnostic tools and the 
potential harms and benefits of the different diagnostic 
tools. Table 1 shows an overview of the advantages and 
disadvantages of available diagnostic tools (49).
Clinical consequences
Patients with NAFLD are at increased risk of atherosclerotic 
cardiovascular disease (asCVD). A recent meta-analysis 
showed that NAFLD was associated with an increased 
risk of fatal and non-fatal cardiovascular disease (odds 
ratio 2.58 (1.78–3.75)) (50). Interestingly, in patients with 
recently diagnosed myocardial infarction, the severity of 
stenosis on coronary angiography was found to correlate 
with the degree of hepatic steatosis on conventional 
ultrasound as well as VCTE-CAP (50). Moreover, the 
cumulative risk for mortality has shown to be increased 
in patients with coronary disease and stage 3-steatosis 
compared to patients with coronary disease and stage 1- 
and 2-steatosis (51, 52).
Whilst these studies all show a strong association 
between hepatic steatosis and cardiovascular disease, 
a recent European population-based cohort study 
with 120.795 NAFLD patients versus matched controls 
showed that when adjusting for age, smoking, diabetes, 
hypertension, total cholesterol levels and statin use 
the hazard ratios for acute myocardial infarction (AMI) 
are lower than firstly calculated (53). This suggests that 
NAFLD is likely not an independent risk factor for asCVD, 
but may be driving asCVD by exacerbating risk factors like 
hypertension, insulin resistance and dyslipidaemia (50, 
54). Causal pathways by which NAFLD may drive asCVD 
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and prothrombotic factors, most notably PAI-1. Favouring 
the lipid link and as mentioned previously, Mendelian 
randomization studies show that variation in the gene 
PNPLA3, involved in steatosis without affecting plasma 
lipid levels, does not increase the risk of asCVD, whereas 
variation in TM6SF2, affecting both steatosis and plasma 
VLDL, does increase asCVD risk (55). In addition to asCVD, 
NAFLD is related to cardiovascular disease by influencing 
left ventricular function. A recent study showed decreased 
left ventricular function within patients with NAFLD-
fibrosis (56).
Given the strong association between NAFLD, mixed 
lipidaemia and asCVD, treatment with statins to lower 
the lipid levels and decrease the risk on the development 
of cardiovascular events is important and has shown to be 
safe in a variety of large studies (57).
Besides this increased risk of adverse cardiovascular 
outcomes, increasing evidence has shown NAFLD can 
develop into a seriously harmful disease also with regards 
to liver-related outcomes, contrary to previous beliefs 
(58). Especially in patients with active disease, i.e. NASH, 
the formation of fibrosis and cirrhosis increases morbidity 
and mortality. A recent meta-analysis has shown that for 
patients with NASH it takes circa 7.1 years to progress 1 
stage in fibrosis compared to circa 14.3 years for patients 
with simple steatosis (59). Importantly, NAFLD patients 
with T2DM are at higher risk of developing advanced liver 
fibrosis than NAFLD patients without diabetes (60, 61). 
Data from the American Transplant Registry show that 
in 2018, NAFLD/NASH-related cirrhosis became the main 
indication for liver transplantation, overtaking other liver 
diseases such as viral hepatitis and alcoholic liver disease 
(ALD), and this indication is on the rise in Europe as well 
(62, 63). An additional problem is that the amount of 
liver donors with signs of NAFLD is also rising, increasing 
the risk of post-transplantation complications for the 
recipient (63).
Since liver cirrhosis is a well-known risk factor for 
development of HCC, patients with cirrhosis need to be 
regularly screened. However, not seldom HCC is diagnosed 
in patients that were unfamiliar to have NAFLD, even 
without cirrhosis (64). Possibly due to lack of screening, 
patients with NAFLD that develop HCC have decreased 
survival rates compared to HCC patients with underlying 
alcoholic liver cirrhosis (65). Screening for HCC in NAFLD 
patients is however debatable, since the incidence of HCC 
in NAFLD patients is low, demonstrated by a large meta-
analysis that found an annual incidence of 0.44 per 1000 
person-years. In patients diagnosed with NASH, the HCC 
incidence was 5.29 per 1000 person-years (5).
Treatment
The complexity of the various pathways involved in the 
development of NAFLD complicates the treatment of this 
disease. Given the strong association with obesity and 
T2DM, lifestyle changes and weight loss are major targets 
in treatment of NAFLD and NASH. However, the increasing 
knowledge on an abundance of pathophysiological 
mechanisms that are involved, combined with the 
increase in incidence and severity of this disease has led 
to an enormous pharmaceutical development (66, 67).
Lifestyle and nutritional interventions
Lifestyle intervention is the most important factor in 
the treatment of NAFLD (68, 69). A weight reduction of 
8% has been shown to result in a 50% decrease in liver 
fat (69). Yet an increase in physical activity without 
any reduction in body weight also has a positive effect 
on hepatic steatosis (69). In patients with NASH, a strict 
52-week programme of physical activity and diet resulted 
in a resolution of NASH in 25% of patients and 19% of 
patients showed regression of fibrosis. The extent of 
weight loss was associated with the level of improvement 
in histologic features of NASH. However, the vast majority 
of patients in this study did not reach the 5% weight 
loss goal, reflecting the difficulty of lifestyle changes in 
this specific population (70). On the other hand, studies 
have shown that doubling of daily calorie intake in 
healthy volunteers with so-called fast food resulted in 
elevated plasma ALT levels and increased steatosis within 
4 weeks (71).
Especially foods and beverages containing large 
amounts of fructose, like sodas, have shown to have 
a cumulative effect on the development of NAFLD and 
even fibrosis (72). Lifestyle changes and weight reduction 
are expected to remain centrally important within the 
treatment of NAFLD, since they not only exert positive 
effects on NAFLD but also on associated metabolic and 
cardiovascular diseases. Even modest alcohol use has been 
shown to mitigate the ability of the body to resolve NASH 
and is associated with increased serum liver enzymes, 
suggesting patients with NAFLD should completely cease 
their alcohol use (73). Moreover, certain dietary changes, 
like the Mediterranean diet, consisting of mainly single 
unsaturated fats derived from fish or olive oil, help to 
reduce the amount of liver fat and insulin insensitivity, 
even without inducing body weight reduction (74). 
Limiting the amount of free sugars in the diet was 
also shown to have a positive effect on NAFLD (69). 
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Interestingly, the use of three or more cups of coffee a 
day protects against NAFLD and the formation of fibrosis, 
possibly through an increase in autophagia of lipid 
droplets within hepatocytes (75).
However, not only caloric intake, but also dietary 
composition has shown to play a role through dysbiosis 
of the gut microbiota, which most likely contributes to 
the development of NAFLD and NASH (27, 76, 77, 78, 79). 
A diet rich in lipids, animal-derived proteins and sugars 
provides a more favourable culture medium for certain 
bacterial species (like Bacteroides) than for others (80, 81). 
However, the mechanisms that underlie the development 
of NASH through microbiome imbalance are not fully 
understood. One hypothesis is that certain bacterial 
compositions increase gut permeability, thereby exposing 
the portal vein and liver to (products of) gut bacteria 
that induce various inflammatory pathways. Another 
hypothesis is that gut bacteria may induce or protect 
against NAFLD by producing pro- or anti-inflammatory 
metabolites. Both harmful metabolites, such as alcohol, 
as well as protective metabolites, like butyrate produced 
by Eubacterium hallii, have been identified as possible 
mechanisms in the development of hepatic steatosis in 
recent murine models (82). A recent study revealed that 
presence of high-alcohol-producing strains of Klebsiella 
pneumoniae in the gut was strongly associated with disease 
severity in a Chinese cohort of NAFLD patients, and that 
this strain could reproduce fatty liver disease in murine 
models. The endogenous alcohol production of these 
bacteria might activate similar molecular mechanisms 
as in fatty liver disease mediated by habitual excessive 
alcohol consumption, which is microscopically nearly 
indistinguishable from NAFLD (83).
Animal models suggest that influencing the gut 
microbial composition by using probiotics can reduce 
NAFLD (80). In humans, a recent placebo-controlled pilot 
study in 20 patients with biopsy-proven NAFLD revealed 
a decrease in hepatic steatosis after 6 months of treatment 
with probiotics consisting of various species such as 
L. plantarum, L. delbueckii spp. bulgaricus, L. acidophilus, 
Lactobacillus rhamnosus and Bifidobacterium bifidum. 
A decrease in hepatic steatosis was found, which was 
associated with an increase in Bacteroides and a decrease 
of Firmicutes species (84).
Gut bacteria also play an important role in the 
modification of bile acids. The dysbiosis of the microbiome 
can lead to alterations in bile acid composition, 
potentially modifying the absorption and metabolism of 
lipids, resulting in a dysregulation of energy metabolism 
(28, 85).
Bariatric surgery and endobariatric procedures
Bariatric surgery has been proven to be very effective in 
NALFD patients, a reduction in body weight of over 10% 
can lead to complete regression of hepatic inflammation 
and fibrosis (86, 87). The Lille Bariatric cohort study 
showed that in morbidly obese patients with biopsy-
proven NASH, bariatric surgery (i.e. gastric banding, 
sleeve gastrectomy and gastric bypass) resulted in a 
resolution of NASH in 85% of patients and a reduction in 
fibrosis (86). Gastric bypass has been shown to be more 
effective in improving NAFLD and NASH compared to 
other procedures (88).
Moreover, new endobariatric techniques have been 
developed to fill the gap for patients who do not qualify 
for bariatric surgery or prefer less invasive strategies. 
Endoscopic gastroplication has shown to be a durable, 
less invasive therapy providing results similar to sleeve 
gastrectomy. But also other endobariatric procedures 
like space-occupying devices, aspiration therapy and 
endoscopic small bowel bypass therapies have been 
proven to be successful in inducing weight loss (89, 90). 
A single-centre retrospective cohort study following 135 
patients with obesity and NAFLD undergoing intragastric 
balloon (IGB) treatment revealed changes in BMI after 
6 months, as well as corresponding improvement of 
ALT, GGT and insulin resistance (HOMA-IR) scores 
(91). However, as endobariatric interventions are often 
temporary or less durable than bariatric surgery, aggressive 




Due to the close link between NAFLD and glycaemic 
dysregulation, blood glucose-lowering drugs also retain 
therapeutic effects in patients with hepatic steatosis. 
Treatment with metformin, a mainstay therapy in T2DM, 
showed to be associated to mitigation of steatosis in 
patients with NASH (92) and to prevent hepatic events in 
T2DM patients with advanced NASH (93).
Whereas metformin mainly affects hepatic insulin 
resistance, GLP-1-receptor agonists and analogues 
(liraglutide and semaglutide, respectively exenatide) have 
direct effects on pancreatic insulin production and also 
impact the heart, brain and gastrointestinal system (94). 
Despite the lack of unambiguous data about a direct effect 
of these medications on the liver, studies have suggested 
liraglutide to have a positive effect on NASH and the 
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formation of fibrosis by reducing body weight, even in 
patients without T2DM (95). Moreover, liraglutide has 
shown to result in a reduction of asCVD events in patients 
with T2DM (96). However, strict rules for financial 
reimbursement for these medications, limiting off-label 
clinical use, and the need for s.c. injections to administer 
the drugs are hampering broader clinical implications. An 
oral form of the GLP-1 analogue semaglutide is currently 
in development for the treatment of NAFLD (66) and has 
already shown to have positive results in patients with 
T2DM in a phase 3-study (97).
Another group of therapeutics, SGLT2 inhibitors, 
such as canagliflozin, dapagliflozin and empaglifozin, 
selectively block the sodium glucose cotransporter 2 in 
the kidneys, thereby inhibiting renal glucose reabsorption 
in the proximal tubule. This increases urinary glucose 
excretion and reduces blood glucose levels in patients 
with T2DM. Results from multiple clinical NAFLD trials 
have shown SGLT2 inhibitors to significantly decrease 
serum liver enzyme levels compared to other oral glucose-
lowering agents (98). Moreover, animal models of NASH 
demonstrated that treatment with SGLT2 inhibitors could 
prevent the development of hepatic steatosis and fibrosis, 
possibly by promoting fat utilization and by reducing de 
novo lipogenesis in the liver (99). In addition, canagliflozin 
has demonstrated to reduce asCVD events in patients 
with T2DM (100). However, SGLT2 inhibitors increase the 
risk of diabetic ketoacidosis, urinary tract infections and 
hypotension and dehydration, and the effect is minimized 
by the amount of serum glucose that can be excreted via 
the urine, which is estimated at 50%. The alleviation of 
hyperglycaemia and the induction of weight loss only 
partially explain the extent of NAFLD improvement with 
SGLT2 inhibitors, suggesting the involvement of other, 
still unknown pathways. Because of safety concerns and 
the limited effects of the established drugs on-going 
research is seeking novel/safer SGLT2 inhibitors.
Furthermore, thiazolidinediones like pioglitazone and 
rosiglitazone (withdrawn from the market in 2010), which 
increase insulin sensitivity, have been shown to exert 
positive effects on NAFLD through PPARγ-agonism (101, 
102, 103). Unfortunately, they have disadvantages such 
as an increase in body weight, negative cardiovascular 
effects (mainly rosiglitazone) and a possible increased risk 
of bladder cancer (104).
Inflammation and necro-apoptosis
Selonsertib is an ASK1 inhibitor that was recently 
investigated in two phase 3-studies, one in F3-fibrosis and 
one in F4-fibrosis. Both studies report negative, that is, 
no significant effect of selonsertib on hepatic steatosis, 
inflammation or fibrosis (105, 106).
CCR2/5 antagonists
Cenicriviroc is a CCR2/5 antagonist, inhibiting 
macrophages in the peripheral fat tissue, which improves 
insulin sensitivity and inhibits migration, activation and 
proliferation of stellate cells. A phase 2 trial concluded 
cenicriviroc has positive effects on hepatic steatosis, 
inflammation and fibrosis and a phase 3-trial is currently 
being performed (107, 108).
Vitamin E
Vitamin E is a well-known antioxidant and exerts a 
positive effect on the amount of liver fat when prescribed 
in high doses (800 IE a day) (103). Unfortunately, no data 
have been collected on the effect of vitamin E on fibrosis, 
and high doses also seem to increase risk of prostate 
cancer and cerebrovascular accidents (CVA) (109, 110). 
The European Association for the Study of the Liver (EASL) 
Clinical Practice Guidelines (developed in collaboration 
with the associations for diabetes and obesity) advise 
to consider vitamin E for patients with severe NAFLD 
(without T2DM) (3).
Lipid-lowering drugs
Although there have been safety concerns in the past about 
the prescription of statins in patients with elevated serum 
liver enzymes, these medications seem to have positive 
effects not only by decreasing risk of cardiovascular disease 
but also by inhibiting formation of hepatic fibrosis (111). 
Moreover, multiple agents are being developed to block 
the de novo lipogenesis within the liver, most notably 
ACC-inhibitors, and phase 2 and 3-trials are expected to 
read out in the near future (58).
Thyromimetics
Thyroid hormone and thyroid mimetics have the 
potential to reduce NAFLD-NASH. There are signs that 
these hormones exert positive effects on hepatic steatosis 
by mediating the induction of autophagia of lipid droplets 
and mitochondrial beta-oxidation of fatty acids (112). In 
20 patients with T2DM and NAFLD, a low dose of thyroid 
hormone resulted in significant reduction of intrahepatic 
fat, measured by MRI-PDFF (113). A phase 2-trial in which 
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78 NASH patients were treated with a selective thyroid 
hormone receptor beta-agonist showed a significant 
reduction of intrahepatic fat measured by MRI-PDFF and 
an improvement of NASH on liver biopsy after 36 weeks 
(114). Therefore, a phase-3 trial with this selective thyroid 
hormone receptor beta-agonist is ongoing (115).
Bile acids
Besides their function in the absorption of lipids in the 
gut, there is accumulating evidence suggesting that bile 
acids also play a major role as signalling molecules in the 
liver and gut. Bile acids regulate the energy metabolism 
of lipids, sugars and proteins (28, 116). There are multiple 
on-going clinical trials using bile acid derivatives and 
mimetics as possible treatment for NASH (117, 118, 119, 
120, 121, 122).
Ursodeoxycholic acid (a tertiary bile acid) and 
colesevelam (an anion exchange resin) have no effect on 
the amount of liver fat (65, 123). However, in the phase- 
2 FLINT trial the FXR-agonist obeticholic acid (OCA) 
did result in a histologic response of NASH in 46% of 
the participants with 25 mg a day (compared to 21% in 
the placebo group) (124). Unfortunately, a commonly 
reported side effect (23%) was pruritus, as well as an 
elevation in plasma LDL, due to increased lipoprotein 
lipase (LPL) activity. Interim analysis of the REGENERATE 
trial, a phase-3 trial concerning OCA in NASH, showed a 
small but significant reduction of fibrosis compared to the 
placebo group (125).
Combination therapy
Because of the complex pathogenesis of the disease, future 
medical treatment of progressive NAFLD is expected to 
consist of combination therapy, analogous to the current 
treatment of T2DM and hypertension. This expectation 
is so strong, that two types of combination therapy are 
already being investigated in clinical trials, even before 
the first monotherapy for NAFLD has been registered. In 
the phase-2 TANDEM trial, the FXR-agonist tropifexor is 
combined with cenicriviroc (126). In the phase-2 ATLAS 
trial, selonsertib is being combined with ACC-inhibition 
and a FXR-agonist. An early interim analysis did not show 
synergy in reducing hepatic steatosis on MRI-PDFF, yet 
the final results have to be awaited (127). Interestingly, 
both studies combine a drug that acts upstream (insulin 
sensitivity/lipotoxicity) in the pathogenesis of NAFLD with 
a drug that acts more downstream (apoptosis, fibrosis), 
which seems a highly plausible approach. Another recent 
randomized controlled trial investigated the combination 
of OCA and atorvastatin in NASH patients. It was shown 
that the OCA-dependent rise in LDL can be mitigated by 
atorvastatin, offering a potentially safer treatment option 
for NASH than OCA alone (128).
Multidisciplinary approach
NAFLD has become a serious health problem and patients 
with NAFLD often suffer from major cardiometabolic 
comorbidities. In recognizing patients with a high-risk 
profile for the development of NASH, the collaboration 
of the general practitioner, assistant nurse, internist-
endocrinologist, vascular specialist and hepatologist 
is essential. In many medical centres across the globe, 
initiatives to develop a NASH-workgroup have sprouted, 
to stimulate this collaboration.
When patients are diagnosed with NAFLD, it is often 
not well recognized which patients suffer from non-
progressive simple steatosis, which patients suffer from the 
metabolically active NASH with high risk of developing 
cardiovascular diseases and which patients have a high 
risk of developing cirrhosis and HCC. Developing more 
accurate and non-invasive diagnostic tools is necessary for 
a better capability of screening and differentiating between 
the different stages of liver disease, providing estimations 
for the chance of progression and the development of 
cirrhotic complications including HCC.
Meanwhile, in the absence of a widely available, 
accurate, non-invasive diagnostic tool, Fig. 3 provides 
recommendations for screening, diagnostics and 
surveillance in (suspected) NAFLD cases. It is advised to 
screen patients with a high risk for NAFLD by three-yearly 
measurements of serum liver enzymes or ultrasonography. 
In case of elevated serum liver enzymes or steatosis on 
ultrasound, screening for the presence of severe fibrosis 
or cirrhosis by VCTE™ or FibroScan® is indicated. In the 
presence of severe fibrosis or cirrhosis, surveillance of 
HCC should take place every 6 months. In case of portal 
hypertension screening for oesophageal varices is also 
indicated.
Another area of concern for these patients is the 
high risk of the development of cardiovascular diseases. 
Intensifying support for lifestyle improvement and 
treating comorbidities remains the cornerstone in 
halting the progression of liver disease and preventing 
cardiovascular complications of NAFLD. No clear 
pharmaceutical treatment has yet been established for 
NAFLD. However, considering the numerous on-going 
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trials, the development of therapeutic agents is expected 
in the near future. Until then, individual considerations 
have to be made in which therapeutic abilities, patient 
characteristics, patient preferences and potential harms 
and benefits of different treatment strategies should 
be taken into account. A multidisciplinary approach 
is essential to identify the patient population in need 
of this care and to ensure it being delivered. With this 
intent the flow chart in Fig. 3 has been composed, based 
on screening methods used in the United Kingdom and 
current guidelines (3, 35, 39, 45, 129, 130).
Conclusion
The increasing prevalence of NAFLD/NASH is worrisome, 
rendering this spectrum of liver disease a major global 
health problem. The challenge to distinguish mild stages 
from progressive stages of NAFLD and the upcoming 
advent of specific pharmacotherapy both require 
improvement of care paths for patients with NAFLD, 
guided by multidisciplinary guidelines and modules. 
Together this renders the clinical developments and 
scientific efforts within the field of NAFLD both very 
challenging and highly fascinating.
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